Oppenheimer Comments on TherapeuticsMD Inc’s Q2 2019 Earnings (NASDAQ:TXMD)

Share on StockTwits

TherapeuticsMD Inc (NASDAQ:TXMD) – Equities research analysts at Oppenheimer increased their Q2 2019 earnings per share (EPS) estimates for shares of TherapeuticsMD in a research report issued on Tuesday, June 11th. Oppenheimer analyst J. Olson now forecasts that the company will post earnings of ($0.14) per share for the quarter, up from their previous forecast of ($0.16). Oppenheimer currently has a “Outperform” rating and a $10.00 target price on the stock. Oppenheimer also issued estimates for TherapeuticsMD’s Q3 2019 earnings at ($0.16) EPS, Q4 2019 earnings at ($0.09) EPS, FY2019 earnings at ($0.55) EPS and FY2023 earnings at $1.20 EPS.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings data on Monday, May 6th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01. TherapeuticsMD had a negative return on equity of 159.71% and a negative net margin of 907.71%. The company had revenue of $3.95 million during the quarter, compared to analyst estimates of $5.96 million. During the same quarter last year, the firm posted ($0.11) EPS. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis.

Several other equities research analysts have also weighed in on TXMD. Zacks Investment Research raised TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Saturday, April 27th. BidaskClub lowered TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Wednesday, April 3rd. ValuEngine lowered TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. Cantor Fitzgerald reissued a “positive” rating on shares of TherapeuticsMD in a report on Thursday, April 18th. Finally, Cowen decreased their price objective on TherapeuticsMD from $16.00 to $9.00 and set an “outperform” rating for the company in a report on Tuesday, June 11th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. TherapeuticsMD presently has an average rating of “Hold” and an average target price of $9.41.

Shares of TXMD opened at $2.44 on Friday. TherapeuticsMD has a fifty-two week low of $2.21 and a fifty-two week high of $7.42. The stock has a market capitalization of $622.35 million, a P/E ratio of -4.14 and a beta of 2.14. The company has a quick ratio of 3.28, a current ratio of 3.39 and a debt-to-equity ratio of 1.26.

Hedge funds and other institutional investors have recently modified their holdings of the business. Metropolitan Life Insurance Co NY increased its stake in TherapeuticsMD by 8.2% in the 1st quarter. Metropolitan Life Insurance Co NY now owns 60,906 shares of the company’s stock worth $296,000 after purchasing an additional 4,627 shares during the period. FMR LLC increased its stake in TherapeuticsMD by 0.5% in the 1st quarter. FMR LLC now owns 18,178,211 shares of the company’s stock worth $88,527,000 after purchasing an additional 89,870 shares during the period. Daruma Capital Management LLC increased its stake in TherapeuticsMD by 11.8% in the 1st quarter. Daruma Capital Management LLC now owns 7,111,035 shares of the company’s stock worth $34,631,000 after purchasing an additional 750,235 shares during the period. Goldman Sachs Group Inc. increased its stake in TherapeuticsMD by 41.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 704,516 shares of the company’s stock worth $3,431,000 after purchasing an additional 206,907 shares during the period. Finally, Ellington Management Group LLC purchased a new position in TherapeuticsMD in the 1st quarter worth approximately $142,000. Institutional investors and hedge funds own 78.93% of the company’s stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.

See Also: What is an Initial Public Offering (IPO)?

Earnings History and Estimates for TherapeuticsMD (NASDAQ:TXMD)

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.